These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26960886)

  • 1. [IQWiG confirms significant additional applications for edoxaban ].
    MMW Fortschr Med; 2015 Dec; 157(21-22):86. PubMed ID: 26960886
    [No Abstract]   [Full Text] [Related]  

  • 2. Edoxaban (Lixiana°).
    Prescrire Int; 2017 Jan; 26(178):13-14. PubMed ID: 30730636
    [No Abstract]   [Full Text] [Related]  

  • 3. Edoxaban (Savaysa) for the Prevention of Thromboembolic Events.
    Oung AB
    Am Fam Physician; 2018 Apr; 97(8):529-530. PubMed ID: 29671492
    [No Abstract]   [Full Text] [Related]  

  • 4. Recommendations for oral anticoagulants.
    J Assoc Physicians India; 2014 Jun; 62(6 Suppl):19-27. PubMed ID: 25845124
    [No Abstract]   [Full Text] [Related]  

  • 5. Current Indian scenario on the use of oral anticoagulants.
    J Assoc Physicians India; 2014 Jun; 62(6 Suppl):28-9. PubMed ID: 25845125
    [No Abstract]   [Full Text] [Related]  

  • 6. [Edoxaban is safer than vitamin K antagonists].
    Einecke D
    MMW Fortschr Med; 2013 Sep; 155(16):20. PubMed ID: 24279137
    [No Abstract]   [Full Text] [Related]  

  • 7. [New direct oral oral anticoagulants (DOACs) - indications of DOACs].
    Darius H
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2014 Mar; 49(3):182-90; quiz 191. PubMed ID: 24711238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Edoxaban Was Effective for the Treatment of Deep Vein Thrombosis and Pulmonary Thromboembolism in a Cancer Patient with Antithrombin III Deficiency.
    Kawano H; Maemura K
    Intern Med; 2016; 55(22):3285-3289. PubMed ID: 27853070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target-specific oral anticoagulants and the hospitalist.
    Deitelzweig S; Amin A
    Hosp Pract (1995); 2015; 43(1):1-12. PubMed ID: 25559350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
    Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
    Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
    Brekelmans M; Middeldorp S; Coppens M
    Expert Rev Hematol; 2015 Dec; 8(6):707-25. PubMed ID: 26560872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
    Lip GY; Merino J; Ezekowitz M; Ellenbogen K; Zamoryakhin D; Lanz H; Jin J; Al-Saadi N; Mercuri M; Goette A
    Am Heart J; 2015 May; 169(5):597-604.e5. PubMed ID: 25965706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
    Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
    J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Edoxaban was Effective for Treating Renal Vein Thrombosis in a Patient with Nephrotic Syndrome.
    Shimada Y; Nagaba Y; Nagaba H; Kamata M; Murano J; Kamata F; Okina C; Nonoguchi H; Shimada H; Takeuchi Y
    Intern Med; 2017 Sep; 56(17):2307-2310. PubMed ID: 28794382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
    Giugliano RP; Ruff CT; Rost NS; Silverman S; Wiviott SD; Lowe C; Deenadayalu N; Murphy SA; Grip LT; Betcher JM; Duggal A; Dave J; Shi M; Mercuri M; Antman EM; Braunwald E;
    Stroke; 2014 Aug; 45(8):2372-8. PubMed ID: 24947287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study.
    van Es N; Di Nisio M; Bleker SM; Segers A; Mercuri MF; Schwocho L; Kakkar A; Weitz JI; Beyer-Westendorf J; Boda Z; Carrier M; Chlumsky J; Décousus H; Garcia D; Gibbs H; Kamphuisen PW; Monreal M; Ockelford P; Pabinger I; Verhamme P; Grosso MA; Büller HR; Raskob GE
    Thromb Haemost; 2015 Nov; 114(6):1268-76. PubMed ID: 26271200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Simplified therapy regimen receives recommendation for approval].
    Red
    MMW Fortschr Med; 2015 Jun; 157(11):67. PubMed ID: 26049361
    [No Abstract]   [Full Text] [Related]  

  • 18. Target-specific oral anticoagulants: practice issues for the clinician.
    Plitt A; Giugliano RP
    Hosp Pract (1995); 2014 Aug; 42(3):48-61. PubMed ID: 25255406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Edoxaban or standard therapy with warfarin for stroke prevention in patients with atrial fibrillation?
    Plitt A; Giugliano RP
    Future Cardiol; 2014 Mar; 10(2):153-5. PubMed ID: 24762238
    [No Abstract]   [Full Text] [Related]  

  • 20. Edoxaban: a review in nonvalvular atrial fibrillation.
    McCormack PL
    Am J Cardiovasc Drugs; 2015 Oct; 15(5):351-61. PubMed ID: 26369340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.